Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
Ethics in Research01:56

Ethics in Research

Today, scientists agree that good research is ethical in nature and is guided by a basic respect for human dignity and safety. However, this has not always been the case. Modern researchers must demonstrate that the research they perform is ethically sound.

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Replacing Surrogate Decision-Making with Supported Decision-Making for Minimal Risk Research.

The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics·2026
Same author

Intellectual Disability and Supported Decision-Making in Clinical Research: Anticipating Ethical Challenges.

The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics·2026
Same author

Using Supported Decision-Making to Promote Value-Aligned Research Participation.

The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics·2026
Same author

Supported Decision-Making and the Inclusion of People who Lack Decisional Capacity in Greater than Minimal Risk Research.

The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics·2026
Same author

The next phase in Long COVID research: addressing the ethical challenges in trials of disease-modifying treatments.

EClinicalMedicine·2026
Same author

Surrogate Decision-Making in Carceral Healthcare.

Journal of general internal medicine·2026

関連する実験動画

Updated: Jun 8, 2026

Working with Human Tissues for Translational Cancer Research
07:48

Working with Human Tissues for Translational Cancer Research

Published on: November 26, 2015

臨床研究のリスクの評価

Annette Rid1, Ezekiel J Emanuel, David Wendler

  • 1Department of Bioethics, NIH Clinical Center, Bethesda, MD 20892, USA.

JAMA
|October 7, 2010
PubMed
まとめ

臨床研究参加者の保護には,リスク評価に対する体系的なアプローチが必要です. 研究リスクの体系的評価 (SERR) メソッドは,参加者の安全性を高めるために,認知バイアスを最小限にします.

科学分野:

  • 臨床研究の倫理について
  • リスク評価の方法論
  • 研究における認知バイアス

背景:

  • 倫理的な臨床研究は,不適切なリスクから参加者を保護することにかかっています.
  • 現在のリスク評価は直感的な判断に依存し,認知バイアスに敏感です.
  • 体系的な枠組みの欠如は,参加者の保護を損なう.

研究 の 目的:

  • 研究リスクを客観的に評価するために,新しい方法である研究リスクの体系的評価 (SERR) を導入します.
  • 参加者の安全性を評価する際に認知バイアスの影響を軽減します.
  • 臨床研究監督の倫理的厳格性を高めること.

主な方法:

  • SERRは,研究介入のリスクを評価するための4段階のプロセスを含む.
  • ステップ1:研究介入による潜在的な害を特定する.
  • ステップ2: 7レベルのスケールを用いて,被害の大きさを分類する.
  • ステップ3:各害の確率を定量化または推定する.
  • ステップ4:研究被害の可能性を,許容可能な比較活動と比較する.

主要な成果:

  • SERRは,リスク評価のための構造化された枠組みを提供します.

さらに関連する動画

A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting
14:43

A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting

Published on: January 12, 2018

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

関連する実験動画

Last Updated: Jun 8, 2026

Working with Human Tissues for Translational Cancer Research
07:48

Working with Human Tissues for Translational Cancer Research

Published on: November 26, 2015

A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting
14:43

A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting

Published on: January 12, 2018

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

  • リスクを明示的に区切り,定量化し,比較することは,主観的なバイアスを軽減します.
  • この方法は,より一貫性があり,信頼性の高いリスク評価を容易にする.
  • 結論:

    • SERRは,研究リスク評価における認知バイアスを最小限に抑えるための体系的なアプローチを提供します.
    • この方法は,過剰なリスクから臨床研究参加者の保護を強化します.
    • SERRの実施は,研究研究の倫理的監督を改善することができます.